Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2015

View Archived Issues

Anti-annexin II shows potential as a new biomarker for APS

Resverlogix closes license agreement, enters stock purchase agreement with Hepalink

Monopar partners with Cancer Research UK and Cancer Research Technology on HuATN-658

Allergan patents EP2 receptor agonists

Daiichi Sankyo describes LCAT activators

Sanofi reports dual GIPR/GLP-1R agonists

Sunovion Pharmaceuticals reports P2X4 negative modulators

Bristol-Myers Squibb presents HCV NS5B inhibitors

Epizyme and Celgene extend research collaboration

AstraZeneca divests global rights to Entocort

CB-5083 receives FDA orphan drug designation for multiple myeloma

FDA orphan drug designation granted to Rett's syndrome candidate sarizotan

Etodolac and propranolol combination receives U.S. orphan status for malignant glioma

Genentech's atezolizumab reduces tumor size in phase II urothelial bladder cancer study

sFLT-1 may enable early diagnosis of sickle cell nephropathy

FDA approves Rexulti for schizophrenia and major depressive disorder

Homocitrulline can differentiate acute and chronic renal failure

Canadian trial investigates novel tumor-targeted oncolytic virus vaccine

BioDiem and Griffith University receive grant to study targets of BDM-I

Galectin-3 may be a biomarker of cirrhosis severity

Imbruvica approved in E.U. for Waldenstrom's macroglobulinemia

The Scripps Research Institute to study environmental triggers for autoimmune disease

Novel hyaluronic acid eyedrops promote corneal tissue healing

Benitec acquires full rights to Hepbarna hepatitis B program

Novo Nordisk releases results from first phase IIIa study of semaglutide for type 2 diabetes

EyeGate licenses EGP-437 and delivery technology to Valeant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...